Abstract
Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are rare in solid tumors (<0.35%) yet incidence varies widely across cancer types. The first TRK inhibitor (TRKi) was approved by the FDA in November 2018 (larotrectinib) with a second TRKi (entrectinib) approved August 2019. This research aims to describe the TRKi treatment patterns in patients with NTRK-fusion positive solid tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
